UK Science Facilities Face £162m Funding Crisis With Potential Closures
Britain's world-leading science facilities, including the Diamond Light Source and ISIS Neutron and Muon Source, face potential closure or significant cuts due to a £162m funding crisis at the Science and Technology Facilities Council caused by rising electricity costs, staff expenses, and foreign exchange pressures. These facilities serve hundreds of companies and thousands of scientists domestically and internationally, with Diamond producing light 10 billion times brighter than the sun for materials research. Scientists and research leaders warn that short-term funding cuts could cause decades-long damage to the UK's scientific capability and international competitiveness.
The Science and Technology Facilities Council (STFC) is considering substantial spending cuts to address cost overruns totaling £162m by 2029-30, driven by soaring electricity and staff costs alongside high foreign exchange rates for international collaborations like CERN. Major facilities including Diamond Light Source in Oxfordshire and the ISIS Neutron and Muon Source are being asked to cut between 10% and 20% of annual spending. Diamond, which functions as a giant microscope producing unprecedented detail for materials research from COVID viruses to ancient scrolls, faces approximately 20% reductions that would impact its planned Diamond-II upgrade. ISIS, which has already operated at 80% capacity for two years and lost 10% of staff, uses neutrons and muons to support research across physics, chemistry, materials science, and engineering. Research leaders including physicist Brian Cox and the Institute of Physics chief executive have warned that these cuts represent a threat to the UK's scientific future and international standing, urging the government to consult the research community and reconsider the timeline for these changes.
What different sources said
World-leading UK science facilities at risk amid £162m funding crisis
Related
Researchers Identify D-Retro-Inverso Peptide Candidates for Treating Cardiac Amyloidosis
Researchers have designed and computationally evaluated four peptide candidates made from D-amino acids that may inhibit the formation of Serum Amyloid A (SAA) fibrils associated with cardiac complications following heart attacks. The study builds on mouse model evidence suggesting SAA aggregates contribute to long-term myocardial infarction complications and may operate similarly in humans. Two candidates, DRI-R5S and DRI-H6A, were identified as particularly promising for potential drug development.
Study Identifies D-Retro-Inverso Peptides as Potential Treatments for Cardiac Amyloidosis
Researchers designed four peptide candidates using D-amino acids to inhibit Serum Amyloid A (SAA) fibril formation, which may contribute to complications following heart attacks. The study, conducted using molecular dynamics simulations in a mouse model, identified two peptides—DRI-R5S and DRI-H6A—as promising drug candidates. This work could lead to new therapeutic approaches for cardiac amyloidosis, a serious post-infarction complication.
Scientists Discover Previously Unknown Branch of Tryptophan Metabolism in Humans
Researchers identified a new enzymatic step in human tryptophan catabolism, showing that the protein ASPDH acts as a 2-aminomuconate reductase to produce a previously unknown amino acid. This discovery fills a gap in the kynurenine pathway, one of the body's major metabolic routes for processing the amino acid tryptophan. The finding expands understanding of human metabolism and may have implications for understanding NAD cofactor production and related metabolic diseases.